Related Experiment Video
Updated: Jan 27, 2026
The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
Published on: November 30, 2016
IMB0901 inhibits muscle atrophy induced by cancer cachexia through MSTN signaling pathway
Dong Liu1, Xinran Qiao1, Zhijuan Ge1
1Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, 1# Tiantan Xili, Dongcheng District, Beijing, 100050, China.
Background:
Cancer cachexia as a metabolic syndrome can lead to at least 25% of cancer deaths. The inhibition of muscle atrophy is a main strategy to treat cancer cachexia. In this process, myostatin (MSTN) can exert a dual effect on protein metabolism, including inhibition of protein biosynthesis and enhancement of protein degradation. In this study, we will test the effect on muscle atrophy induced by cancer cachexia of IMB0901, a MSTN inhibitor.
Methods:
Two high-throughput screening models against MSTN were developed. By screening, IMB0901, 2-((1-(3,4-dichlorophenyl)-1H-pyrazolo [3,4-d] pyrimidin-4-yl) amino) butan-1-ol, was picked out from the compound library. The in vitro cell model and the C26 animal model of muscle atrophy induced by cancer cachexia were used to determine the pharmacological activity of IMB0901. Whether IMB0901 could inhibit the aggravating effect of doxorubicin on muscle wasting was examined in vitro and in vivo.
Results:
IMB0901 inhibited the MSTN promoter activity, the MSTN signaling pathway, and the MSTN positive feedback regulation. In atrophied C2C12 myotubes, IMB0901 had a potent efficiency of decreasing MSTN expression and modulating MSTN signaling pathway which was activated by C26-conditioned medium (CM). In C2C12 myotubes, the expressions of three common myotube markers, myosin heavy chain (MyHC), myogenic differentiation 1 (MyoD), and myogenin (MyoG), were downregulated by CM, which could be efficiently reversed by IMB0901 via reduction of ubiquitin-mediated proteolysis and enhancement of AKT/mTOR-mediated protein synthesis. In the C26 animal model, IMB0901 mitigated the weight loss of body, quadricep and liver, and protected the quadriceps cell morphology. Furthermore, IMB0901 decreased the expression of two E3 ligases Atrogin-1 and MuRF-1 in the quadriceps in vivo. At the cellular level, IMB0901 had no influence on anti-tumor effect of three chemotherapeutic agents (cisplatin, doxorubicin, and gemcitabine) and lowered doxorubicin-induced upregulation of MSTN in C2C12 myotubes. IMB0901 did not affect the inhibitory effect of doxorubicin on C26 tumor and delayed the weight loss of muscle and adipose tissue caused by C26 tumor and doxorubicin.
Conclusions:
IMB0901 inhibits muscle atrophy induced by cancer cachexia by suppressing ubiquitin-mediated proteolysis and promoting protein synthesis. These findings collectively suggest that IMB0901 is a promising leading compound for the management of muscle atrophy induced by cancer cachexia.
Insights
IMB0901, a myostatin (MSTN) inhibitor, combats cancer cachexia by reducing muscle atrophy. It suppresses protein breakdown and boosts protein synthesis, showing promise for treating this condition.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Cancer cachexia is a metabolic syndrome causing significant cancer-related mortality.
- Inhibiting muscle atrophy is crucial for managing cancer cachexia.
- Myostatin (MSTN) plays a dual role in protein metabolism, inhibiting synthesis and promoting degradation.
Purpose of the Study:
- To evaluate the efficacy of IMB0901, a novel MSTN inhibitor, in mitigating muscle atrophy associated with cancer cachexia.
- To investigate the molecular mechanisms underlying IMB0901's effects on muscle protein metabolism.
- To assess IMB0901's impact on cachexia in preclinical cancer models.
Main Methods:
- Developed high-throughput screening models to identify MSTN inhibitors.
- Utilized in vitro cell models (C2C12 myotubes) and an in vivo C26 animal model of cancer cachexia.
- Assessed IMB0901's effects on MSTN signaling, protein synthesis/degradation pathways, and myotube markers.
- Examined IMB0901's interaction with chemotherapeutic agents like doxorubicin.
Main Results:
- IMB0901 effectively inhibited MSTN promoter activity and signaling pathways.
- In vitro, IMB0901 reversed cachexia-induced downregulation of myotube markers by reducing proteolysis and enhancing AKT/mTOR signaling.
- In vivo, IMB0901 mitigated body and muscle weight loss, protected muscle morphology, and reduced E3 ligase expression (Atrogin-1, MuRF-1).
- IMB0901 did not impede anti-tumor effects of chemotherapy and lessened doxorubicin-induced MSTN upregulation.
Conclusions:
- IMB0901 demonstrates potent anti-atrophy effects in cancer cachexia models.
- The compound functions by suppressing ubiquitin-mediated proteolysis and promoting protein synthesis.
- IMB0901 represents a promising therapeutic candidate for managing muscle atrophy in cancer cachexia.
More Related Videos
10:50Tibial Nerve Transection - A Standardized Model for Denervation-induced Skeletal Muscle Atrophy in Mice
Published on: November 3, 2013
07:15A Cell-based Assay to Investigate Non-muscle Myosin II Contractility via the Folded-gastrulation Signaling Pathway in Drosophila S2R+ Cells
Published on: August 19, 2018
Related Concept Videos
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
03:14Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
02:33Hedgehog Signaling Pathway
01:28Insulin: The Receptor and Signaling Pathways
01:11IP3/DAG Signaling Pathway
01:28Nitric Oxide Signaling Pathway